治疗严重高甘油三酯血症的新型药物。
Novel agents for treating severe hypertriglyceridemia.
作者信息
Wierzbicki Anthony S
机构信息
Department of Metabolic Medicine/Chemical Pathology, Guy's & St Thomas' Hospitals, London, UK.
出版信息
Med. 2024 Dec 13;5(12):1446-1448. doi: 10.1016/j.medj.2024.10.019.
The PALISADE trial extended the data available for inhibition of apolipoprotein (apo) C3 inhibition for treating severe hypertriglyceridemia. 75 patients with persistent chylomicronemia were allocated to 2 doses of plozasiran or placebo. Triglycerides were reduced by a net 53%-58%, and a borderline significant 17% reduction was seen in pancreatitis events. These results offer potential treatments for familial or multifactorial chylomicronemia syndromes.
PALISADE试验扩展了有关抑制载脂蛋白（apo）C3治疗严重高甘油三酯血症的可用数据。75例持续性乳糜微粒血症患者被分配接受2种剂量的普洛扎西兰或安慰剂治疗。甘油三酯净降低了53%-58%，胰腺炎事件减少了17%，具有临界显著性。这些结果为家族性或多因素乳糜微粒血症综合征提供了潜在的治疗方法。
Zotero 插件